Manasa Patil News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Manasa patil. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Manasa Patil Today - Breaking & Trending Today

Investegate |Evgen Pharma PLC Announcements | Evgen Pharma PLC: Result of General Meeting & Total Voting Rights

Investegate |Evgen Pharma PLC Announcements | Evgen Pharma PLC: Result of General Meeting & Total Voting Rights
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Borough Of Cheshire East , United Kingdom , City Of , Huw Jones , Evgen Pharmaplcwww , Evgen Pharma , Geoff Nash Teddy Whiley , Richard Moulson , Paul Mcmanus Anna Dunphy , London Stock Exchange , General Meeting , Placing Shares , Open Offer , Disclosure Guidance , Teddy Whiley , Corporate Finance , Manasa Patil , Liverpool Science Park , London Stock , Abuse Regulation , Persons Discharging Managerial Responsibilities , Stock Exchange , பெருநகர ஆஃப் செஷயர் கிழக்கு , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , ஹ ஜோன்ஸ் ,

Synairgen plc: Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients

Synairgen plc: Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
( Synairgen or the Company )
Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
Southampton, UK - 13 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that the first patient has been dosed in the UK as part of its global Phase III trial (SG018) evaluating Synairgen s inhaled formulation of interferon beta-1a (SNG001), for the treatment of hospitalised COVID-19 patients.
As previously announced, Synairgen has appointed Parexel Biotech, a division of the leading global clinical research organisation, Parexel, to help conduct the Phase III trial and several UK sites have now been initiated, with further sites in the US and the EU expected to follow. The trial is ....

United Kingdom , Olivia Manser , Carina Jurs , Geoff Nash , Richard Marsden , John Ward , Donna Davies , Duncan Monteith , James Black , Mary Jane Elliott , Ratko Djukanovic , Kate Bannatyne , Freddie Barnfield , Numis Securities Limited Joint Broker , United Kingdom National Institute For Health Research , University Of Southampton Professors Sir Stephen Holgate , Urgent Public Health , Drug Administration , Consilium Strategic Communications Financial Media , Parexel Biotech , National Institute , Health Research , Fast Track , Market Abuse Regulation , Chief Executive , Charlie Beeson ,

Investegate |Synairgen plc Announcements | Synairgen plc: First Patient Dosing in Phase III SG018 Trial

About Synairgen

Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. Synairgen is currently fully focused on progressing its inhaled interferon beta

broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection.

Synairgen s differentiating human biology BioBank platform and world-renowned international academic KOL network has broader applicability for lung viral defence in other respiratory disorders including asthma and COPD. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see
www.synairgen.com

SNG001 (inhaled Interferon beta) applicability to COVID-19 ....

United Kingdom , Olivia Manser , Carina Jurs , Geoff Nash , Richard Marsden , John Ward , Donna Davies , Duncan Monteith , James Black , Mary Jane Elliott , Ratko Djukanovic , Kate Bannatyne , Freddie Barnfield , Numis Securities Limited Joint Broker , United Kingdom National Institute For Health Research , University Of Southampton Professors Sir Stephen Holgate , Urgent Public Health , Drug Administration , Consilium Strategic Communications Financial Media , Parexel Biotech , National Institute , Health Research , Fast Track , Market Abuse Regulation , Chief Executive , Charlie Beeson ,